Related Experiment Video
Updated: May 21, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers
Bernhard Homey1, Peter Arne Gerber, Andreas Wollenberg
1Hautklinik, Universitätsklinikum Düsseldorf, Germany. bernhard.homey@uni-duesseldorf.de
Abstract:
Recommendations for the management of cutaneous adverse effects of inhibitors of the epidermal growth factor receptor (EGFR) are urgently needed. In this context an expert panel of German dermatologists recently proposed a 3-step management concept based on personal experience and a current literature consensus. While steps 1 and 2 addressed general and preventive measures, as well as the therapy that can be performed by the primary treating physician, here we address the management of challenging cases (step 3) that do not respond well to basic measures and should be referred to an experienced dermatologist.
Related Concept Videos
Mitogens and the Cell Cycle
Clinical Applications of Epidermal Stem Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
